Sustained Elevation of Vascular Endothelial Growth Factor and Angiopoietin-2 Levels After Transcatheter Aortic Valve Replacement

2016 ◽  
Vol 32 (12) ◽  
pp. 1454-1461 ◽  
Author(s):  
Jeremy Ben-Shoshan ◽  
Arie Steinvil ◽  
Yaron Arbel ◽  
Yan Topilsky ◽  
Leehee Barak ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Aortic Valve ◽  
Aortic Valve Replacement ◽  
Valve Replacement ◽  
Transcatheter Aortic Valve Replacement ◽  
Vascular Endothelial ◽  
Transcatheter Aortic Valve ◽  
Angiopoietin 2 ◽  
Endothelial Growth Factor

scholarly journals Systemic Bevacizumab for Refractory Bleeding and Transfusion-Dependent Anemia in Heyde Syndrome

2021 ◽  
Author(s):  
Andrew B Song ◽  
Rahul Sakhuja ◽  
Nancy M Gracin ◽  
Ronald Weinger ◽  
Raj S Kasthuri ◽  
...  
Keyword(s):  
Aortic Valve ◽  
Aortic Valve Replacement ◽  
Valve Replacement ◽  
Antiangiogenic Therapy ◽  
Severe Bleeding ◽  
Vascular Endothelial ◽  
The Novel ◽  
Transcatheter Aortic Valve ◽  
Red Cell Transfusion ◽  
Endothelial Growth Factor

Heyde syndrome, the co-occurrence of aortic stenosis and bleeding gastrointestinal angiodysplasia, is managed with aortic valve replacement. However, severe bleeding and anemia can preclude safe use of the antiplatelet or anticoagulant therapy required for this intervention. We present a case of the novel and successful treatment of severe, refractory bleeding and transfusion-dependence with antiangiogenic therapy in a patient with Heyde syndrome. Following initiation of systemic bevacizumab, the patient achieved durable hemostasis with normalization of hemoglobin, liberation from red cell transfusion and iron infusion dependence, and successful initiation of aspirin therapy where it had previously failed. This facilitated her subsequent successful transcatheter aortic valve replacement. Plasma vascular endothelial growth factor levels, which were monitored during therapy, rose paradoxically after initiation of bevacizumab and normalized after its discontinuation. Given the angiogenic dysregulation of Heyde syndrome, systemic bevacizumab may be an effective and safe targeted therapy for management of refractory gastrointestinal bleeding, thereby facilitating antiplatelet therapy and aortic valve replacement in these challenging cases. Additional investigation into the therapeutic role of angiogenesis inhibition as a hemostatic modality in Heyde syndrome is warranted.

Epidemiology of infective endocarditis in transcatheter aortic valve replacement: systemic review and meta-analysis

2020 ◽  
Vol 21 (10) ◽  
pp. 790-801 ◽  
Author(s):  
Narut Prasitlumkum ◽  
Wasawat Vutthikraivit ◽  
Sittinun Thangjui ◽  
Thiratest Leesutipornchai ◽  
Jakrin Kewcharoen ◽  
...  
Keyword(s):  
Infective Endocarditis ◽  
Aortic Valve ◽  
Aortic Valve Replacement ◽  
Valve Replacement ◽  
Transcatheter Aortic Valve Replacement ◽  
Meta Analysis ◽  
Systemic Review ◽  
Transcatheter Aortic Valve
Sign in / Sign up

Export Citation Format

Share Document